Patents by Inventor Christopher Dinsmore

Christopher Dinsmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS
    Publication number: 20140349998
    Abstract: The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer, by administering the pyrrolo[2,3-d]pyrimidine-derivative compounds of formula I.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 27, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sean P Ahearn, Matthew Christopher, Christopher Dinsmore, Joon Jung, Qinglin Pu, Alexey Rivkin, Mark E. Scott, David J. Witter, Hyun Chong Woo, Brandon Cash
  • AZAINDOLES AS JANUS KINASE INHIBITORS
    Publication number: 20140303142
    Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Application
    Filed: September 28, 2012
    Publication date: October 9, 2014
    Inventors: John W. Butcher, David Witter, Christopher Dinsmore, June Kim, John Hendrix, Raksha Acharya, Sean P. Ahearn, Joon Jung, Alexey Rivkin, Philip Jones
  • CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS
    Publication number: 20140243309
    Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 28, 2014
    Inventors: Jason Brubaker, Christopher Dinsmore, Dawn Marie Hoffman, Joon Jung, Duan Liu, Scott Peterson, Tony Siu, Luis E. Torres, Hongjun Zhang, Zhongyong Wei, Feng Shi
  • Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
    Patent number: 8329722
    Abstract: The instant invention provides for compounds that inhibit JAK2 tyrosine kinase and/or PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting JAK2 tyrosine kinase activity and/or PDK1 kinase inhibitory activity by administering the compound to a patient in need of treatment or prevention of myeloproliferative disorders or cancer.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: December 11, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tony Siu, Jonathan Young, Michael Altman, Alan Northrup, Ekaterina Kozina, Christopher Dinsmore, David J. Guerin, Kevin A. Keenan, Joon O. Jung, Solomon Kattar, Rachel N. MacCoss
  • PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS
    Publication number: 20120220624
    Abstract: The present invention is directed to novel kinase inhibitors of general formula (I) and pharmaceutically acceptable salts thereof, and to the use of the kinase inhibitors of general formula (I) for treating diseases or disorders in which tau phosphorylation and cell cycle regulation is implicated, such as Alzheimer's Disease and cancer.
    Type: Application
    Filed: September 29, 2010
    Publication date: August 30, 2012
    Inventors: Tony Siu, Christopher Dinsmore, E. Sathyajith Kumarasinghe
  • INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1
    Publication number: 20100160309
    Abstract: The instant invention provides for compounds that inhibit JAK2 tyrosine kinase and/or PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting JAK2 tyrosine kinase activity and/or PDK1 kinase inhibitory activity by administering the compound to a patient in need of treatment or prevention of myeloproliferative disorders or cancer.
    Type: Application
    Filed: March 10, 2008
    Publication date: June 24, 2010
    Inventors: Tony Siu, Jonathan Young, Micheal Altman, Alan Northrup, Ekaterina Kozina, Christopher Dinsmore, David J. Guerin, Kevin A. Keenan, Joon O. Jung, Solomon Kattar, Rachel N. MacCoss
  • Tyrosine kinase inhibitors
    Publication number: 20080008708
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: August 7, 2007
    Publication date: January 10, 2008
    Inventors: Christopher Dinsmore, Douglas Beshore, Jeffrey Bergman, Craig Lindsley
  • Tyrosine kinase inhibitors
    Publication number: 20070173525
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: April 2, 2007
    Publication date: July 26, 2007
    Inventors: Annette Kim, Craig Stump, Christopher Dinsmore, Samuel Graham, Theresa Williams, Diem Nguyen, B. Trotter
  • Quinoline potassium channel inhibitors
    Publication number: 20070078154
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: April 5, 2007
    Inventors: Christopher Dinsmore, Jeffrey Bergman
  • Isoquinoline potassium channel inhibitors
    Publication number: 20070054892
    Abstract: The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 22, 2004
    Publication date: March 8, 2007
    Inventors: Richard Isaacs, Christopher Dinsmore, B. Trotter, Nigel Liverton, Douglas Beshore, Nathan Kett, Charles McIntyre, Kausik Nanda, David Claremon
  • Quinoline potassium channel inhibitors
    Publication number: 20070043042
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: February 22, 2007
    Applicant: MERCK & CO., INC.
    Inventors: Christopher Dinsmore, Jeffrey Bergman
  • Tyrosine kinase inhibitors
    Publication number: 20060293358
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 22, 2006
    Publication date: December 28, 2006
    Inventors: Christopher Dinsmore, Ana Gabarda Ortega, David Guerin, James Jewell, Jason Katz, Jongwon Lim, Michelle Machacek, Ryan Otte, Jonathan Young
  • Isoquinolinone potassium channel inhibitors
    Publication number: 20060281743
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: December 14, 2006
    Inventor: Christopher Dinsmore
  • Isoquinoline potassium channel inhibitors
    Publication number: 20060276450
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: December 7, 2006
    Inventors: B. Trotter, Kausik Nanda, Nathan Kett, Christopher Dinsmore, Gerald Ponticello, David Claremon
  • Isoquinolinone potassium channel inhibitors
    Publication number: 20060270704
    Abstract: The present invention relates to compounds having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 22, 2004
    Publication date: November 30, 2006
    Inventors: Richard Isaacs, Christopher Dinsmore, Charles McIntyre, Linda Payne, David Claremon
  • Tyrosine kinase inhibitors
    Publication number: 20060128783
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: August 5, 2003
    Publication date: June 15, 2006
    Inventors: Christopher Dinsmore, Douglas Beshore, Jeffrey Bergman, Craig Lindsley
  • Potassium channel inhibitors
    Publication number: 20060030595
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: July 25, 2005
    Publication date: February 9, 2006
    Inventors: Mark Bilodeau, Christopher Dinsmore, Jeffrey Bergman, B. Trotter, Lou Neilson, Zhicai Wu, Peter Manley, John Hartnett
  • Tyrosine kinase inhibitors
    Publication number: 20050261496
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: August 5, 2003
    Publication date: November 24, 2005
    Inventors: Christopher Dinsmore, Douglas Beshore, Jeffrey Bergman, Craig Lindsley
  • Tyrosine kinase inhibitors
    Publication number: 20050239815
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: April 8, 2003
    Publication date: October 27, 2005
    Inventors: Annette Kim, Craig Stump, Christopher Dinsmore, Samuel Graham, Theresa Williams, Diem Nguyen, B. Wesley Trotter
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6248756
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferas (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: June 19, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Christopher Dinsmore, Robert P. Gomez, John H. Hutchinson, John S. Wai, Theresa M. Williams, Ian M. Bell, Mark W. Embrey, Thorsten E. Fisher